title: Long-term outcome and intervention of urea cycle disorders in Japan.
abstract: Urea cycle disorders (UCDs) are one of the most frequently inherited metabolic diseases in Japan, with an estimated prevalence of 1 per 50,000 live births. Here, we investigated the clinical manifestations, treatment, and prognosis of 177 patients with UCDs who were evaluated and treated from January 1999 to March 2009. These included 77 cases of neonatal-onset UCDs and 91 cases of late-onset UCDs. The most common UCD was ornithine transcarbamylase deficiency (OTCD), which accounted for 116 out of 177 patients. This result is similar to a previous study performed between 1978 and 1995 in Japan: OTCD accounted for about two-thirds of the total number of UCD cases. We studied the relationship between prognosis and the peak blood ammonia level at the onset in 151 UCD patients. Compared with a previous survey conducted in Japan, we found that a greater number of patients survived without any mental retardation despite their peak blood ammonia levels being greater than 360 μmol/l. The 5-year survival rate of patients with OTCD improved to 86% for those with the neonatal-onset type and to 92% for those with the late-onset type. We hypothesize that the increased survival rate is due to early diagnosis and better treatments that are now available in Japan. It is very important to diagnose and treat UCDs, especially OTCD, when the blood ammonia levels in patients are low. The outcome in patients with low blood ammonia levels was better than that in patients with high blood ammonia levels.
authors.affiliation: Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto Prefecture 860-8556, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Kido
authors.forename: Kimitoshi
authors.initials: K
authors.lastname: Nakamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mitsubuchi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Ohura
authors.forename: Masaki
authors.initials: M
authors.lastname: Takayanagi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Matsuo
authors.forename: Makoto
authors.initials: M
authors.lastname: Yoshino
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: Tohru
authors.initials: T
authors.lastname: Yorifuji
authors.forename: Mureo
authors.initials: M
authors.lastname: Kasahara
authors.forename: Reiko
authors.initials: R
authors.lastname: Horikawa
authors.forename: Fumio
authors.initials: F
authors.lastname: Endo
mesh_terms: D017668:Age of Onset; D000641:Ammonia / Q000097:blood* / Q000378:metabolism*; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D020163:Ornithine Carbamoyltransferase Deficiency Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D014508:Urea / Q000378:metabolism*; D056806:Urea Cycle Disorders, Inborn / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000641:Ammonia; D014508:Urea